Publication | Open Access

Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)

Breast OncologyOncologyMedicinePathologyImmune Checkpoint InhibitorBreast CancerPharmacotherapyCancer TreatmentPharmacologyRadiation OncologyDose-finding Combination StudyOvarian Cancer